Genentech's $47M upfront payment seals molecular glue collaboration with Orionis Biosciences

Genentech has entered into a molecular glue partnership with Orionis BioSciences, a biotech company based in Boston and Ghent, Belgium, for the discovery and optimization of small molecule molecular glues targeting undisclosed targets in cancer and neurodegeneration. Genentech will pay Orionis $47 million upfront and has committed to over $2 billion in potential downstream milestones. Genentech will take over the preclinical and clinical development of the drug candidates.